Navigation Links
EORTC study opens for elderly patients with HER-2 positive metastatic breast cancer
Date:6/19/2013

Despite the fact that the incidence of cancer is many fold higher in persons over 65 years of age, we still have an inadequate understanding on how best to treat these older cancer patients. Furthermore, even though elderly patients are occasionally included in clinical trials, those elderly patients who are eventually included are mostly 'healthy' (fit) elderly patients. Thus, the broader elderly patient population is not well represented in clinical trials. The EORTC Cancer in the Elderly Task Force is now starting a new phase 2 trial in precisely this group of patients: EORTC 75111 10114 for non-fit elderly patients with HER-2 positive metastatic breast cancer.

Overall survival for patients with HER-2 positive breast cancer is improved with a combination of chemotherapy and agents that specifically target the HER-2 (human epidermal growth factor receptor 2) gene. Chemotherapy, however, is often accompanied with side effects that can adversely affect health related quality of life in elderly patients. EORTC trial 75111-10114 attempts to find out if HER-2 targeted regimens with minimal toxicity for the elderly population might delay, or even completely obviate, the use of conventional chemotherapy. New HER-2 targeted strategies have created an opportunity to try this strategy.

Patients who progress under pertuzumab and trastuzumab will be allowed to switch to Trastuzumab-DM1 conjugate (T-DM1), another recently available targeted therapy. The binding of trastuzumab to the cell allows intracellular delivery of the cytotoxic agent DM1. The trastuzumab-DM1 conjugate has been shown to have a favorable toxicity profile.

The main objectives of EORTC trial 75111 10114 are to evaluate the efficacy as measured by progression free survival at six months following treatment with pertuzumab combined with trastuzumab or pertuzumab combined with trastuzumab plus metronomic chemotherapy in elderly metastatic breast cancer patients and to select a
'/>"/>

Contact: John Bean
john.bean@eortc.be
European Organisation for Research and Treatment of Cancer
Source:Eurekalert

Page: 1 2

Related medicine news :

1. EORTC intergroup trial opens for patients with resected head of pancreas adenocarcinoma
2. EORTC BOS 2 trial opens for patients with resectable liver metastases from colorectal cancer
3. EORTC study shows radiotherapy and surgery provide regional control for breast cancer patients
4. Markers in Cancer, a joint meeting by ASCO, EORTC & NCI, 7-9 Nov 2013 (diagnostic tutorial on 5-7)
5. EORTC study identifies patients with anaplastic oligodendroglioma that benefit from adjuvant PCV
6. EORTC led intergroup trial investigates Imatinib failure-free survival in patients with GIST
7. Media alert: 24th EORTC - NCI - AACR Symposium Molecular Targets and Cancer Therapeutics
8. New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz
9. Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments
10. UT Dallas study suggests new approach to fight lung cancer
11. Whooping cough has lifelong health impact, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... California (PRWEB) March 30, 2015 ... as radioactive isotopes, radiopharmaceuticals are used as tracers ... global market for radiopharmaceuticals is driven by the ... in the field of cardiology, neurology, pulmonology, and ... by the well-established use of radioisotopes in diagnostic ...
(Date:3/30/2015)... Daily sun exposure, stressors and environmental factors ... folds and other giveaways of age. However, advances in ... to hit the pause button, delaying the impact of ... or hack to rejuvenate any facial feature. , ... (AAFPRS) explores the intricacies of The Aging Face ...
(Date:3/30/2015)... March 30, 2015 Mid-America ATTC ... library of medications used in behavioral health and ... iPad and Android—is a convenient, electronic version of ... 1999. The useful resource provides up-to-date information on ... and frequency, side effects, emergency conditions, cautions, considerations ...
(Date:3/30/2015)... 2015 BioFit Engineered ... manufacturer of ergonomic seating solutions, now offers ... new upholsteries bolster the company’s existing selection ... providing disinfectable, green choices. , The BioFit ... purveyor CF Stinson. Six disinfectable patterns consisting ...
(Date:3/29/2015)... 2015 At the 2015 International Health ... introduced the new Fonda wall mounted heater and ... Club owners and facilities managers with saunas smaller than ... design of the Fonda heater. With an attractive ... an immediate upgrade for a sauna, especially when mounted ...
Breaking Medicine News(10 mins):Health News:Expanding Commercial Use in Nuclear Imaging Drives Demand for Radiopharmaceuticals, According to a New Report by Global Industry Analysts, Inc. 2Health News:Expanding Commercial Use in Nuclear Imaging Drives Demand for Radiopharmaceuticals, According to a New Report by Global Industry Analysts, Inc. 3Health News:Expanding Commercial Use in Nuclear Imaging Drives Demand for Radiopharmaceuticals, According to a New Report by Global Industry Analysts, Inc. 4Health News:New AAFPRS Infographic Addresses Concerns and Provides Aging Face Solutions 2Health News:Popular Publication on Behavioral Health Medications Now An App 2Health News:BioFit Adds Bleachable Upholstery Options to Seating Line 2Health News:Helo Commercial Introduces Fonda Sauna Heater and Sauna and Steam Continuing Education Program at IHRSA 2
... new and novel computer modeling platform developed through intensive, ... and cities to be more prepared for catastrophic public ... American Medical Association,s Disaster Medicine and Public Health ... to Multihazard Modeling and Simulation," is based on the ...
... Telemedicine, Mammography and Health Screenings on Wheels Expand Access ... June 11 Kaiser Permanente, one of America,s leading ... a new generation of mobile health. A first-of-its-kind, 500-sq-foot, ... home island of Hawaii, known to many as the ...
... off brain cell damage, lab study finds , THURSDAY, June ... may start with one protein that somehow goes astray and ... say. , Mad cow disease is considered a prion disease ... prion protein, or PrP, which normally is found on the ...
... is pleased to offer its stock alerts service to ... move and in the news can receive FREE Alerts by visiting ... , Today,s focused alerts include: Hemispherx Biopharma, Inc. (Amex: ... Cell Therapeutics, Inc. (Nasdaq: CTIC ), Cancer Therapeutics Inc. ...
... June 11 National figures, stars from the world of sports ... gathered today in Anaheim, California to celebrate 20 years of Drug ... reach of every American in need at the National Association of ... , Speaking in front of a crowd representing every U.S. state ...
... most common cancers in China. Although the association between ... studied, the relation between smoking, alcohol drinking, family history ... cancer still remains uncertain. So it is important to ... of sporadic colorectal cancer. A research team led ...
Cached Medicine News:Health News:A new computer modeling program can help hospitals prepare for the worst 2Health News:Kaiser Permanente Unveils the Nation's Most Wired Mobile Health Vehicle 2Health News:Kaiser Permanente Unveils the Nation's Most Wired Mobile Health Vehicle 3Health News:Protein Branded As Culprit in Mad Cow Disease 2Health News:GlobalEquityReport.com Issues Cancer Stocks On The Move Today: HEB, GNBT, CTIC, CTHP, DNDN 2Health News:U.S. Drug Czar Addresses 2,500 Drug Court Professionals, Voices Strong Support for Expanding Drug Courts Throughout the Nation 2Health News:U.S. Drug Czar Addresses 2,500 Drug Court Professionals, Voices Strong Support for Expanding Drug Courts Throughout the Nation 3
(Date:3/30/2015)... -- RnRMarketResearch.com adds "CountryFocus: Healthcare, Regulatory and ... research report of 295 pages with latest updates, data ... The report " CountryFocus: Healthcare, Regulatory and Reimbursement ... and analysis of the healthcare, regulatory and reimbursement landscape ... key trends in the country,s healthcare market, and provides ...
(Date:3/30/2015)... RALEIGH, N.C. , March 30, 2015 /PRNewswire/ ... announced that the primary efficacy endpoint in the ... compared to placebo for the treatment of painful ... certain secondary endpoints showed statistically significant improvement over ... the product was observed.  The results of this ...
(Date:3/30/2015)... 30, 2015 China Nepstar Chain Drugstore ... a leading retail drugstore chain in China based ... announced its unaudited financial results for the fourth ... Financial HighlightsFor the quarter ended December 31, 2014: ... compared to the fourth quarter of 2013 ...
Breaking Medicine Technology:Spain Medical Devices Market Worth $12 Billion With 4.5% CAGR to 2020, Says RnRMarketResearch.com 2Spain Medical Devices Market Worth $12 Billion With 4.5% CAGR to 2020, Says RnRMarketResearch.com 3Spain Medical Devices Market Worth $12 Billion With 4.5% CAGR to 2020, Says RnRMarketResearch.com 4Spain Medical Devices Market Worth $12 Billion With 4.5% CAGR to 2020, Says RnRMarketResearch.com 5BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 2BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 3BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 4BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 5China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 11China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 12China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 13China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 14China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 15
... Corporation (Nasdaq: LMNX ) today announced financial ... September 30, 2010.  Financial and operating highlights include the ... $33.9 million, a 16 percent increase over the third ... system bringing affordable multiplexing to laboratories worldwide Third ...
... Nov. 4, 2010 eResearchTechnology, Inc. (ERT), (Nasdaq: ... services to the pharmaceutical, biotechnology, and medical device industries, ... ended September 30, 2010.  Unless otherwise noted, all comparative ... year ago.  The financial results for the third quarter ...
Cached Medicine Technology:Luminex Corporation Reports Third Quarter 2010 Results 2Luminex Corporation Reports Third Quarter 2010 Results 3Luminex Corporation Reports Third Quarter 2010 Results 4Luminex Corporation Reports Third Quarter 2010 Results 5Luminex Corporation Reports Third Quarter 2010 Results 6Luminex Corporation Reports Third Quarter 2010 Results 7Luminex Corporation Reports Third Quarter 2010 Results 8Luminex Corporation Reports Third Quarter 2010 Results 9ERT Reports Third Quarter 2010 Results 2ERT Reports Third Quarter 2010 Results 3ERT Reports Third Quarter 2010 Results 4ERT Reports Third Quarter 2010 Results 5ERT Reports Third Quarter 2010 Results 6ERT Reports Third Quarter 2010 Results 7ERT Reports Third Quarter 2010 Results 8ERT Reports Third Quarter 2010 Results 9ERT Reports Third Quarter 2010 Results 10ERT Reports Third Quarter 2010 Results 11ERT Reports Third Quarter 2010 Results 12ERT Reports Third Quarter 2010 Results 13
... Superior optics and workmanship are the hallmark ... temperature sensitivity in mind. The top (incident) ... illumination, eliminating shadows while remaining cool to ... are available with 10x to 44x zoom ...
... system expandability: the first inverted microscope to ... infinity space. Multi-port design enables optical input/output ... variety of illumination and detector equipment. Extendable ... an optional light source and other attachments ...
... The OLY-150 is an monochrome IR/DIC video camera. ... give you all the image quality and flexibility ... video cameras provide a high-resolution, real-time image of ... a video monitor or TV. You can even ...
... automatic fluorescence photomicrography system that greatly simply ... most difficult specimens. Designed with real life ... solution to the complex problem of fluorescence ... control, the system utilizes special programs designed ...
Medicine Products: